Meglucon

Metformin, the active ingredient in Meglucon, is a biguanide presented as an oral tablet for oral use. It is employed to lower elevated blood glucose levels in adults with type 2 diabetes mellitus and in individuals with impaired glucose tolerance, and to improve peripheral insulin sensitivity as part of a comprehensive diabetes management plan under medical supervision.

GNH USA supplies Meglucon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance.

Meglucon (metformin) is used to manage disorders of glucose metabolism, primarily type 2 diabetes and related conditions.

Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial blood glucose. Impaired glucose tolerance (prediabetes): delays progression to overt diabetes by reducing hepatic glucose output. Polycystic ovary syndrome (off‑label): may improve insulin resistance and menstrual regularity in some patients.

Metformin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite. - Diarrhoea: frequent loose stools, especially at treatment initiation. - Metallic taste: transient alteration in taste perception. - Weight loss: modest reduction in body weight over time.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening accumulation of lactate, presenting with rapid breathing and muscle pain. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Vitamin B12 deficiency: may develop with long‑term therapy, leading to neuropathy.

Before initiating Meglucon, several safety considerations should be evaluated. - Renal function assessment: ensure estimated glomerular filtration rate is ≥45 mL/min/1.73 m² before starting. - Hepatic status review: avoid use in patients with severe liver disease. - Monitor blood glucose: adjust dose based on glycaemic response and avoid hypoglycaemia when combined with other agents. - Elderly patients: start at lower dose and monitor for accumulation due to reduced renal clearance. - Contrast imaging precaution: discontinue metformin at least 48 hours before and after iodinated contrast studies in patients with impaired renal function. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase risk of lactic acidosis. - Cimetidine: can raise plasma metformin concentrations, increasing toxicity risk. - Alcohol excess: enhances lactate production and raises lactic acidosis risk.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycaemia. - Diuretics (especially thiazides): can affect renal function and metformin clearance. - ACE inhibitors or ARBs: monitor renal function and electrolytes when combined.